Q4 2024 ACADIA Pharmaceuticals Inc Earnings Call Transcript
Key Points
- ACADIA Pharmaceuticals Inc (ACAD) reported strong financial results with total revenue of $957.8 million for 2024, up 32% from the prior year.
- DAYBUE and NUPLAZID, ACADIA's commercial brands, achieved record quarterly revenues, with DAYBUE sales increasing by 97% year-over-year.
- The company has submitted a marketing application for trofinetide with the European Medicines Agency, marking its first potential approval outside North America.
- ACADIA has expanded its pipeline with new programs, including ACP-711 for essential tremor and ACP-204 for Lewy Body Dementia Psychosis.
- The company strengthened its balance sheet with the sale of a priority review voucher, increasing its cash balance to $756 million by the end of 2024.
- ACADIA Pharmaceuticals Inc (ACAD) anticipates a sequential decline in DAYBUE net product sales in Q1 2025 due to seasonal factors and changes in gross-to-net pricing.
- The company faces challenges in expanding DAYBUE's market penetration, with only 30% of Rett syndrome patients having tried the drug to date.
- NUPLAZID's market share in patients receiving atypical antipsychotics for Parkinson's-related hallucinations and delusions remains at only 25%, indicating room for growth but also highlighting competitive pressures.
- The gross-to-net adjustments for DAYBUE and NUPLAZID are expected to increase due to the Medicare Part D redesign, impacting net pricing.
- ACADIA's R&D expenses are projected to increase in 2025, driven by clinical and personnel costs, which may affect profitability despite expected revenue growth.
Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals conference call. My name is Shannon, and I will be your coordinator for today.
I would now like to turn the presentation over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications at ACADIA. Please proceed.
Thank you. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's fourth-quarter and full-year 2024 earnings. Joining me on the call today from ACADIA are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks; followed by Tom Garner, our Chief Commercial Officer, who will discuss our strong commercial brands, DAYBUE and NUPLAZID.
Also joining us today is Elizabeth Thompson, PhD, Executive Vice President and Head of Research and Development, who will provide an update on our pipeline programs; and Mark Schneyer, our Chief Financial Officer, who will review the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
